ArcticZymes Technologies ASA (AZT.OL)

NOK 13.58

(-2.3%)

Market Cap (In NOK)

693.54 Million

Revenue (In NOK)

118.93 Million

Net Income (In NOK)

19.42 Million

Avg. Volume

87.1 Thousand

Currency
NOK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
12.34-43.2
PE
-
EPS
-
Beta Value
0.967
ISIN
NO0010014632
CUSIP
R1010E106
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Michael Benjamin Akoh
Employee Count
-
Website
https://arcticzymes.com
Ipo Date
2005-11-04
Details
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.